US Pharma MarketingEMA’s CHMP grants PRIME status to AbelZeta’s C-CAR168
EMA’s CHMP grants PRIME status to AbelZeta’s C-CAR168 is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
The EMA’s CHMP has granted PRIME designation to AbelZeta Pharma’s C-CAR168, an autologous anti-CD20/BCMA CAR-T therapy.
Source: Pharmaceutical Technology